--- title: "Sino Biopharmaceutical meldet Abschluss der Patienteneinschreibung für Phase-III-Studie von Tecotabart Vedotin bei Magenkrebs" type: "News" locale: "en" url: "https://longbridge.com/en/news/275237363.md" description: "Sino Biopharmaceutical Limited has announced the successful completion of patient enrollment for the Phase III registration study of Tecotabart Vedotin (LM-302), an antibody-drug conjugate targeting CLDN18.2. The study focuses on patients with CLDN18.2-positive, locally advanced or metastatic gastric and gastroesophageal junction carcinoma in third-line and later therapy. LM-302 is the first CLDN18.2-ADC to complete patient enrollment in a pivotal Phase III study. Early phase study results combining LM-302 with Toripalimab were presented at the ASCO Annual Meeting 2025." datetime: "2026-02-08T22:13:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275237363.md) - [en](https://longbridge.com/en/news/275237363.md) - [zh-HK](https://longbridge.com/zh-HK/news/275237363.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275237363.md) | [繁體中文](https://longbridge.com/zh-HK/news/275237363.md) # Sino Biopharmaceutical meldet Abschluss der Patienteneinschreibung für Phase-III-Studie von Tecotabart Vedotin bei Magenkrebs Sino Biopharmaceutical Limited hat bekannt gegeben, dass die Patientenaufnahme für die Phase-III-Zulassungsstudie von Tecotabart Vedotin (LM-302), einem Antikörper-Wirkstoff-Konjugat (ADC) gegen CLDN18.2, erfolgreich abgeschlossen wurde. Die Studie richtet sich an Patienten mit CLDN18.2-positivem, lokal fortgeschrittenem oder metastasiertem Magen- und gastroösophagealem Übergangskarzinom in der Drittlinien- und späteren Therapie. LM-302 ist das weltweit erste CLDN18.2-ADC, das die Patientenaufnahme in einer zulassungsrelevanten Phase-III-Studie abgeschlossen hat. Ergebnisse einer frühen Phase-Studie zur Kombination von LM-302 mit Toripalimab wurden auf dem ASCO-Jahrestreffen 2025 vorgestellt. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12018666), on February 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [SINO BIOPHARM (01177.HK)](https://longbridge.com/en/quote/01177.HK.md) - [JUNSHI BIO (01877.HK)](https://longbridge.com/en/quote/01877.HK.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [Junshi Biosciences (688180.CN)](https://longbridge.com/en/quote/688180.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) ## Related News & Research - [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md) - [03:03 ETSectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging](https://longbridge.com/en/news/277900089.md) - [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md) - [Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib](https://longbridge.com/en/news/277705715.md) - [Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%](https://longbridge.com/en/news/277421361.md)